Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling ........ 1394
Précis: ctDNA profiling of pre- and post-treatment samples from patients with localized lung cancer identifies the presence of minimal residual disease earlier than standard imaging.
See commentary, p. 1368

Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells ........ 1404
Précis: Endothelial activation and vascular disruption were associated with a high risk of severe neurotoxicity in 133 patients with B-cell malignancies treated with CD19-targeted CAR-T cell therapy.
See commentary, p. 1371

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer ... 1420
Précis: Analysis of immune checkpoint inhibitor–resistant lung tumors revealed that loss of B2M expression may impair antigen processing to promote acquired resistance in patients with lung cancer.
ON THE COVER Neurologic adverse events induced by autologous transfer of CD19-targeted chimeric antigen receptor-modified T (CAR-T) cells were investigated in 133 patients with B-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, or non-Hodgkin lymphoma who had received chemotherapy and CD19 CAR-T cell infusion. Cytokine release syndrome (CRS) preceded neurotoxicity in all 28 patients who developed grade 3+ neurotoxicity, and severe neurotoxicity was linked to endothelial activation and increased blood–brain barrier permeability. Signs of endothelial activation and vascular disruption were observed in the brain of a patient who died of CRS-induced neurotoxicity, and endothelial activation prior to treatment was linked to an increased risk of high-grade neurotoxicity. Altogether, these results identify risk factors for CD19 CAR-T cell therapy–induced neurotoxicity, and suggest that endothelial activation may serve as a biomarker for severe neurotoxicity. For details, please see the article by Gust, Hay, Hanafi, and colleagues on page 1404.
CANCER DISCOVERY

7 (12)

Cancer Discov 2017;7:OF3-1481.

Updated version
Access the most recent version of this article at:
http://cancerdiscovery.aacrjournals.org/content/7/12

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://cancerdiscovery.aacrjournals.org/content/7/12.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.